Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Transactions
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of common stock on April 8, 2025.
Summary
- On April 8, 2025, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., exercised non-qualified stock options to acquire 2,000 shares of common stock at a price of $10.60 per share.
- Simultaneously, Malik sold 2,000 shares of common stock at a price of $36.18 per share.
- Following these transactions, Malik directly owns 140,255 shares of Cytokinetics Inc. common stock and 27,105 non-qualified stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 03/28/2017 | Date the Non-Qualified Stock Option was granted. |
| 02/28/2027 | Expiration date of the Non-Qualified Stock Option. |
| 04/08/2025 | Date of stock option exercise and stock sale. |
Keywords
Form 4, Cytokinetics, Stock Options, Stock Sale, Beneficial Ownership, Insider Trading, Malik Fady Ibraham
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.